₱1,050.00
Co-amoxiclav (Inovox) 625 mg is a white to off-white film coated tablet, biconvex, oval shaped and plain on both sides, Co-amoxiclav is an oral antibacterial combination consisting of the synthetic antibiotic amoxicillin and B- lactamase inhibitor, clavulanate potassium (the potassium salt of clavulanic acid). Amoxicillin Trihydrate is an analog of ampicillin, derived from the basic penicillin nucleus, 6-aminopenicillanic acid. The Amoxicillin Trihydrate molecular formula is C16H, 9N3O5S«3H2O, and the molecular weight is 419.46. Chemically, amoxicillin is (2S, 5R, 6R)-6[(R)-(-)-2-Amino-2 (4-hydroxyphenyl) acetamido]-3, 3-dimethyl-7-oxo-4-thia-1-azabicycl o [3.2.0] heptane-2-carboxylic acid trihydrate and may be represented structurally as:
Clavulanic acid is produced by fermentation of Streptomyces clavuligerus. It is a B-lactam structurally related to the penicillins and possesses the ability to inactivate a wide variety of B-lactamases by blocking the active sites of these enzymes. Clavulanic acid is particularly active against the clinically important plasmid-mediated B-lactamases frequently responsible for transferred drug resistance to penicillins and cephalosporins. The clavulanate potassium molecular formula is C9HSKNO5, and the molecular weight is 237.25. Chemically, clavulanate potassium is potassium (ZH2R,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]-heptane-2-carboxylat e and may be represented structurally as:
REMINDER: A doctor prescription is required to purchase this product. To avoid delay in delivery or cancellation of your order ,(before the item is SHIPPED), please email a copy of your prescription (.jpeg or .pdf file format) to, ppihag_manila@yahoo.com ,with your order number after Checkout. Our pharmacist will also get in touch with you to validate your prescription.
Each Film-CoatedTablet contains:
Amoxicillin (as trihydrate), USP 500 mg
Clavulanic Acid (as Clavulanate Potassium), USP 125 mg
Co-amoxiclav may be taken without regard to meals; however, absorption of clavulanate potassium is enhanced when co-amoxiclav is administered at the start of a meal. To minimize the potential for gastrointetinal in tolerance, Co-amoxiclav should be taken at the start of a meal.
Adults
The usual adult dose is one625mg tablet ofCo-amoxiclavevery12hours or one 375 mg tablet of
Co-amoxiclav every 8 hours. For more severe infections and infections of the respiratory tract, the dose should be one 1 g tablet of Co-amoxiclav every 12 hours or one 625 mg tablet of Co-amoxiclav every 8hours.Adults who have difficulty swallowing maybe given the 156.25mg/5mLor 312.5 mg/5mLsuspensioninplaceof the625 mg tablet. The228.5 mg/ 5 mL suspension or the 457mg/5mLsuspension may be used in place of 1 g tablet. Duration of therapy studied and recommended for acute otitismediais 10 days.
Patients Weighing 40kg or More:
Pediatric patients weighing 40 kg or more should be dosed according to adult recommendations. The 375 mg tablet of Co-amoxiclav should not be used until the child weighs atleast 40kg, due to the different Co-amoxiclav ratios in the 375mg tablet of Co-amoxiclav (250/ 125) versusthe312.5mg chewable tablet of Co-amoxiclav (250/ 62.5).
Patients with Renal Impairment
Patients with impaired renal function do not generally require are reduction dose unless the impairment is severe. Renal impaired patients with a glomerular filtration rate of <30mL/min should not receive the 1g dose.
Patients with glomerular filtrationof10to 30mL/min should receive 625mg or 375 mg every 12 hours, depending on the severity of the infection. Patients with glomerular filtration rate less than 10mL/min should receive 625 mg or 375 mg every 24 hours, depending on the severity of the infection. Hemodialysis patients should receive 625 mg or 375mg every 24 hours, depending on the severity of the infection. They should receive an additional dose both during and at the end of dialysis.
For the treatment of urinary tract infections due to susceptible organisms, otitismedia or sinusitis due to resistant microorganisms, e.g. H influenzae, S. pneumoniae. M. cartarrhalis, lower respiratory tract and skin infections due to susceptible organisms, polymicrobial infections with mixed aerobic and anaerobic such as diabetic foot, gynecologic infections, intra-abdominal infections.
